{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:44:39Z","timestamp":1785422679622,"version":"3.56.0"},"reference-count":23,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Inhibrx Biosciences, Inc."}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>INBRX-105, a tetravalent, PD-L1\u2013targeted TNFRSF9 (4-1BB) agonist, demonstrated preclinical antitumor activity. This first-in-human study evaluated INBRX-105 in solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This open-label, 4-part, phase 1 study evaluated INBRX-105 alone or with pembrolizumab in adults with locally advanced\/metastatic, unresectable solid tumors (NCT03809624). INBRX-105 was administered intravenously once every 2 weeks or 4 weeks in parts 1 (single-agent dose escalation; 0.001\u20133 mg\/kg) and 2 (single-agent expansion) or once every 3 weeks in parts 3 (combination dose escalation; INBRX-105 0.03\u20131.0 mg\/kg) and 4 (combination expansion). Part 2 enrolled patients with checkpoint inhibitor\u2013relapsed\/refractory (CPI-R\/R) tumors. Part 4 enrolled patients with CPI-R\/R or CPI-na\u00efve disease. The primary endpoint was safety and tolerability of INBRX-105. Preliminary clinical response was a secondary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 160 patients assessed, 81 received monotherapy (median age, 65 years; female, 50.6%), and 79 combination therapy (median age, 64 years; female, 38%). The INBRX-105 maximum tolerated dose was 0.3 mg\/kg once every 3 weeks. Head and neck squamous cell carcinoma (n = 61) and non\u2013small cell lung cancer (n = 25) were the most common tumor types. The most common any-grade INBRX-105\u2013related adverse events (AE) were fatigue (monotherapy, 35.8%; combination, 17.7%), increased aspartate aminotransferase (25.9%; 15.2%), and nausea (19.8%; 17.7%). INBRX-105\u2013related hepatic AEs occurred in 41 patients [monotherapy, n = 25 (grade \u22653, n = 11); combination, n = 16 (grade \u22653, n = 6)]. In all patients, the objective response rate was 8.8% [monotherapy, 3.7%; combination, 13.9% (CPI-na\u00efve, 30%; CPI-R\/R, 8.6%)]; the disease control rate was 43.1%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The low response rates and hepatic safety signals observed do not support further clinical development of INBRX-105.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Tumor resistance to CPIs often develops, underscoring an unmet need. This first-in-human phase 1 trial evaluated INBRX-105\u2014a tetravalent, PD-L1\u2013targeted 4-1BB agonist\u2014alone or with pembrolizumab. Unfortunately, clinical development of INBRX-105 was ended because of hepatotoxicity and limited efficacy. Novel treatment combinations with nonredundant, complementary immunotherapies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0577","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:50:32Z","timestamp":1769550632000},"page":"374-382","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1052-0734","authenticated-orcid":false,"given":"Jong Chul","family":"Park","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"publisher"}],"name":"Massachusetts General Hospital 1 , Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8368-4601","authenticated-orcid":false,"given":"David","family":"Berz","sequence":"additional","affiliation":[{"name":"2Valkyrie Clinical Trials, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9769-0850","authenticated-orcid":false,"given":"Manish R.","family":"Sharma","sequence":"additional","affiliation":[{"name":"3START Center for Cancer Research \u2013 Midwest, Grand Rapids, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8586-0234","authenticated-orcid":false,"given":"Jyoti","family":"Malhotra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope 4 , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6322-9721","authenticated-orcid":false,"given":"Anthony W.","family":"Tolcher","sequence":"additional","affiliation":[{"name":"5NEXT Oncology, San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-7279","authenticated-orcid":false,"given":"Ralph J.","family":"Hauke","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/052z1v370","id-type":"ROR","asserted-by":"publisher"}],"name":"Nebraska Cancer Specialists 6 , Omaha, Nebraska."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8227-7406","authenticated-orcid":false,"given":"Justin A.","family":"Call","sequence":"additional","affiliation":[{"name":"7START Mountain Region, West Valley City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-8989","authenticated-orcid":false,"given":"John T.","family":"Hamm","sequence":"additional","affiliation":[{"name":"8Norton Cancer Institute, Louisville, Kentucky."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-6054","authenticated-orcid":false,"given":"Rachel E.","family":"Sanborn","sequence":"additional","affiliation":[{"name":"9Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-7968","authenticated-orcid":false,"given":"Naomi B.","family":"Haas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 10 , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5233-2466","authenticated-orcid":false,"given":"Frank","family":"Tsai","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03szbwj17","id-type":"ROR","asserted-by":"publisher"}],"name":"HonorHealth 11 , Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-8227","authenticated-orcid":false,"given":"Doug R.","family":"Adkins","sequence":"additional","affiliation":[{"name":"12Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Washington University School of Medicine, Alvin J. Siteman Cancer Center, Barnes-Jewish Hospital, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1280-175X","authenticated-orcid":false,"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[{"name":"13University of Colorado Cancer Center, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1303-0447","authenticated-orcid":false,"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03tbabt10","id-type":"ROR","asserted-by":"publisher"}],"name":"Virginia Cancer Specialists 14 , Fairfax, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3531-5840","authenticated-orcid":false,"given":"Lane","family":"Senne","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pr1pc58","id-type":"ROR","asserted-by":"publisher"}],"name":"Inhibrx Biosciences, Inc. 15 , La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-8601","authenticated-orcid":false,"given":"James","family":"Kalabus","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pr1pc58","id-type":"ROR","asserted-by":"publisher"}],"name":"Inhibrx Biosciences, Inc. 15 , La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9224-952X","authenticated-orcid":false,"given":"Brianne","family":"O\u2019Neill","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pr1pc58","id-type":"ROR","asserted-by":"publisher"}],"name":"Inhibrx Biosciences, Inc. 15 , La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7981-2243","authenticated-orcid":false,"given":"Heather","family":"Kinkead","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pr1pc58","id-type":"ROR","asserted-by":"publisher"}],"name":"Inhibrx Biosciences, Inc. 15 , La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0849-1698","authenticated-orcid":false,"given":"Josep","family":"Garcia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pr1pc58","id-type":"ROR","asserted-by":"publisher"}],"name":"Inhibrx Biosciences, Inc. 15 , La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7798-7286","authenticated-orcid":false,"given":"Erminia","family":"Massarelli","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope 4 , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2026050515111767500_bib1","doi-asserted-by":"crossref","first-page":"e003231","DOI":"10.1136\/jitc-2021-003231","article-title":"Immuno-oncology trends: preclinical models, biomarkers, and clinical development","volume":"10","author":"Franklin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026050515111767500_bib2","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.3390\/cancers14163972","article-title":"Recent advances and challenges in cancer immunotherapy","volume":"14","author":"Peterson","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026050515111767500_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl 3","key":"2026050515111767500_bib4","first-page":"e000733","article-title":"New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis","volume":"4","author":"Etxeberria","year":"2020","journal-title":"ESMO Open"},{"key":"2026050515111767500_bib5","doi-asserted-by":"crossref","first-page":"968360","DOI":"10.3389\/fonc.2022.968360","article-title":"4-1BB: a promising target for cancer immunotherapy","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol"},{"key":"2026050515111767500_bib6","doi-asserted-by":"crossref","first-page":"1225704","DOI":"10.3389\/fimmu.2023.1225704","article-title":"The benefits of clustering in TNF receptor superfamily signaling","volume":"14","author":"Vanamee","year":"2023","journal-title":"Front Immunol"},{"key":"2026050515111767500_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"2026050515111767500_bib8","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-17-1243","article-title":"Phase Ib study of utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors","volume":"23","author":"Tolcher","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026050515111767500_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fonc.2015.00117","article-title":"4-1BB agonists: multi-potent potentiators of tumor immunity","volume":"5","author":"Bartkowiak","year":"2015","journal-title":"Front Oncol"},{"key":"2026050515111767500_bib10","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-17-1847","article-title":"Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27-dependent pathway","volume":"24","author":"Bartkowiak","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026050515111767500_bib11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"Suppl 16","key":"2026050515111767500_bib12","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1200\/JCO.2024.42.16_suppl.2533","article-title":"Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): initial results of a randomized, open-label, phase 2 trial","volume":"42","author":"Aerts","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050515111767500_bib13","doi-asserted-by":"crossref","first-page":"e011377","DOI":"10.1136\/jitc-2024-011377","article-title":"Acasunlimab, an Fc-inert PD-L1\u00d74-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects","volume":"13","author":"Capello","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"Suppl 2","key":"2026050515111767500_bib14","doi-asserted-by":"crossref","first-page":"S711","DOI":"10.1016\/j.annonc.2024.08.1133","article-title":"1075TiP A phase I trial of ATG-101, an investigational PD-L1\u00d74-1BB bispecific antibody, in patients with advanced solid tumors and mature B cell non-Hodgkin lymphomas: PROBE-CN","volume":"35","author":"Xue","year":"2024","journal-title":"Ann Oncol"},{"key":"2026050515111767500_bib15","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/0008-5472.CAN-23-2701","article-title":"ATG-101 is a tetravalent PD-L1\u00d74-1BB bispecific antibody that stimulates antitumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation","volume":"84","author":"Yuwen","year":"2024","journal-title":"Cancer Res"},{"issue":"Suppl 16","key":"2026050515111767500_bib16","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2024.42.16_suppl.2520","article-title":"Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab","volume":"42","author":"Kyi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"2026050515111767500_bib17","first-page":"A12","article-title":"Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4-1BB agonist","volume":"9","author":"Kinkead","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026050515111767500_bib18","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.jtho.2017.07.031","article-title":"Multicenter comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) assays to test PD-L1 expression for NSCLC patients to be treated with immune checkpoint inhibitors","volume":"12","author":"Marchetti","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2026050515111767500_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/his.14562","article-title":"Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study","volume":"80","author":"Cerbelli","year":"2022","journal-title":"Histopathology"},{"key":"2026050515111767500_bib20","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov"},{"key":"2026050515111767500_bib21","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.4049\/jimmunol.178.7.4194","article-title":"Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice","volume":"178","author":"Niu","year":"2007","journal-title":"J Immunol"},{"key":"2026050515111767500_bib22","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00262-010-0846-9","article-title":"Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ","volume":"59","author":"Dubrot","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"2026050515111767500_bib23","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41467-019-10088-1","article-title":"Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with Fc\u03b3R affinity","volume":"10","author":"Qi","year":"2019","journal-title":"Nat Commun"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0577\/3729996\/crc-25-0577.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/374\/3739547\/crc-25-0577.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/374\/3739547\/crc-25-0577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:11:23Z","timestamp":1778008283000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/2\/374\/774724\/Phase-1-Study-of-INBRX-105-a-TNFRSF9-4-1BB-and-PD"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0577","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31387960","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699380","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699392","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387954","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387942","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387930","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387918","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699359","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699404","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387948","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387936","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387924","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699377","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699365","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387951","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387963","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387945","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387933","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387921","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387939","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699407","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387927","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387915","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699413","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31387957","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699398","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699368","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699362","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32699374","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8321491","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}